A PET scan detects several conditions in the body because it shows the chemical activity of the body explicitly. It provides unique details of the body’s anatomic structure and functions that help in diagnosis and appropriate treatment of cancer. The more significant detail and high level of accuracy provided by a PET scan allow doctors to determine the level and stage of cancer and provide proper treatment to patients.
Researchers have developed a single PET-based imaging approach to assess positive tumors. The PD-1 pathway and its ligand PD-L1 are most affected immune checkpoints invaded by tumors thereby weakening the immune responses of the body. But now doctors can administer a tracer safely and non-invasively with a single PET scan to assess tumors and determine the right treatment required.
Below are facts about the single PET scan approach:
- The PET-based imaging approach is used to asses PD-L1 tumors.
- The PD-L1 ligand enables cancer to evade one’s immune system.
- The PD-L1 has been successfully targeted using a fluorine-18(18F)-labelled PD-L1 radioligand. It was then evaluated for distribution, binding and radiation dosimetry and found that the radiation dosimetry and feasibility of the approach estimates indicate that the tracer is safe for use on patients.
- Physicians can now noninvasively assess all the tumors a patient has for PD-L1 expression using a single PET scan and timely readout.
- The single PET scan and readout will help guide the treatment decisions and monitor treatment responses.
- It will help identify the appropriate treatment, the right dose, and the right time of treatment for each patient.
Indications for 18F PET/CT include searching for an unknown primary tumor when metastatic disease is uncovered as a manifestation of cancer. It also indicates differentiating malignant lesions from benign lesions, staging known malignancies, monitoring their effect on therapy, and detecting tumor recurrence.